https://gsk3685032inhibitor.co....m/validity-and-longe
Diligent characteristics of brand-new rivaroxaban users with non-valvular atrial fibrillation changed between 2011 and 2016/17, but changes differed between nations. These patterns have actually methodological implications. They have to be considered within the explanation of observational researches comparing effectiveness and protection of oral anticoagulants, especially regarding possible bias as a result of unmeasured confounding. Use of real-world evidence (RWE) is limited for e
إعجاب
علق
شارك
